Results 301 to 310 of about 5,867,860 (378)

Plasma Proteomic Profile of Chemotherapy‐Induced Severe Neutropenia: A Pilot Discovery Phase Study

The FASEB Journal, Volume 40, Issue 3, 15 February 2026.
Immune system, hemostasis, and protein metabolism are the major biological mechanistic effects affected by chemotherapy‐induced myelotoxicity treatment, which may underline tissue damage and systemic responses seen in patients' follow‐up treatment. ABSTRACT Transient severe neutropenia and thrombocytopenia are frequent during treatment of hematological
Leticia Queiroz da Silva, Alexander Leonardo Silva‐Junior, Licia C. Silva‐Costa, Ivanio Teixeira Borba‐Junior, Bradley J. Smith, Edilson Tadeu Andrade, Bruno Kosa Lino Duarte, Marcos Paulo Colella, Thiago Martins Santos, Daniel Martins‐de‐Souza, Erich Vinicius De Paula   +10 more
wiley   +1 more source

Multi-omics profiling and AI-driven clinically deployable risk models in MGUS and smoldering myeloma. [PDF]

Clin Exp Med
Wu Y, Zhang D, Jiang J, Zheng L, Zhou Z, Zhang Z, Nouri S.   +6 more
europepmc   +1 more source

Changes in protein profiles of multiple myeloma cells in response to bortezomib

, 2012
Taylan Turan, Gülşah Şanlı‐Mohamed, Yusuf Baran   +2 more
openalex   +2 more sources

Targeting the Ubiquitin-Proteasome System for Cancer. [PDF]

MedComm (2020)
Liu Z, Lai J, Ma Z, Pan J, Yang C, Fu R.
europepmc   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

Advanced Science, Volume 13, Issue 7, 3 February 2026.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang   +7 more
wiley   +1 more source

Long non-coding RNAs and therapeutic resistance in multiple myeloma: from molecular insights to clinical applications. [PDF]

Clin Exp Med
Safari MH, Farahani N, Faghih Ojaroodi A, Ebrahimpour A, Cho WC, Zare Khormizi F, Mafi A, Raesi R, Mohammad-Sadeghipour M, Alimohammadi M, Hushmandi K, Hashemi M, Taheriazam A.   +12 more
europepmc   +1 more source

Global, Population and Genetic Evidence on the Relationships Between Immune‐Mediated Inflammatory Disease and Cancer Risk

Cancer Innovation, Volume 5, Issue 1, February 2026.
Using a triangulation framework that synthesizes findings across global, population and genetic perspectives, this work comprehensively establishes associations between six immune‐mediated inflammatory diseases (IMIDs) and 33 cancers, identifying 170 statistically significant IMID‐cancer pairs, validating 20 in the UKBB cohort and uncovering a causal ...
Xuesi Dong, Jiaxin Xie, Zilin Luo, Hao Hong, Chenran Wang, Yadi Zheng, Xiaoyue Shi, Zeming Guo, Xiaolu Chen, Yongjie Xu, Wei Cao, Fei Wang, Dong Hang, Sipeng Shen, Fengwei Tan, Ni Li   +15 more
wiley   +1 more source

Defective mitochondrial unfolded protein response in cancer acts as a lifeline for tumor growth and survival. [PDF]

Cell Stress Chaperones
Sharma U, Vishwas V, Kumar RR, Agarwal N, Shree A, Gorain JK, Sasi A, Sharawat SK, Singh A, Palanichamy JK, Bakhshi S.   +10 more
europepmc   +1 more source

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy [PDF]

, 2019
Azab, Abdel Kareem, Azab, Feda, Fiala, Mark, Fogler, William E., King, Justin, Kohnen, Daniel, Magnani, John L., Muz, Barbara, Smith, Ted, Vij, Ravi   +9 more
core   +1 more source